MX2020005478A - Compuestos de sulfonamida y usos de los mismos. - Google Patents

Compuestos de sulfonamida y usos de los mismos.

Info

Publication number
MX2020005478A
MX2020005478A MX2020005478A MX2020005478A MX2020005478A MX 2020005478 A MX2020005478 A MX 2020005478A MX 2020005478 A MX2020005478 A MX 2020005478A MX 2020005478 A MX2020005478 A MX 2020005478A MX 2020005478 A MX2020005478 A MX 2020005478A
Authority
MX
Mexico
Prior art keywords
sulfonamide compounds
compounds
sulfonamide
preparing
present disclosure
Prior art date
Application number
MX2020005478A
Other languages
English (en)
Inventor
Hiroyuki Nakamura
Jing Teng
Nathan Gignac
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2020005478A publication Critical patent/MX2020005478A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente descripción se refiere a nuevas formas cristalinas de compuestos de sulfonamida, composiciones farmacéuticas que contienen los compuestos de forma cristalina y métodos de preparación y uso de los mismos.
MX2020005478A 2017-11-29 2018-11-28 Compuestos de sulfonamida y usos de los mismos. MX2020005478A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762592023P 2017-11-29 2017-11-29
PCT/IB2018/059430 WO2019106579A1 (en) 2017-11-29 2018-11-28 Sulfonamide compounds and use thereof

Publications (1)

Publication Number Publication Date
MX2020005478A true MX2020005478A (es) 2020-08-27

Family

ID=66665441

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005478A MX2020005478A (es) 2017-11-29 2018-11-28 Compuestos de sulfonamida y usos de los mismos.

Country Status (15)

Country Link
US (2) US12344588B2 (es)
EP (1) EP3717462B1 (es)
JP (1) JP6846574B2 (es)
KR (1) KR102480074B1 (es)
CN (1) CN111386260B (es)
AU (1) AU2018377036B2 (es)
CA (1) CA3084030C (es)
ES (1) ES2969901T3 (es)
MA (1) MA51224A (es)
MX (1) MX2020005478A (es)
MY (1) MY201832A (es)
PH (1) PH12020550703A1 (es)
SG (1) SG11202004877UA (es)
TW (1) TWI762743B (es)
WO (1) WO2019106579A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017275209C1 (en) 2016-05-31 2020-01-23 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
US11439623B2 (en) 2017-04-04 2022-09-13 Case Western Reserve University Method of modulating ribonucleotide reductase
AU2018377036B2 (en) 2017-11-29 2022-04-14 Taiho Pharmaceutical Co., Ltd. Sulfonamide compounds and use thereof
WO2022187200A1 (en) * 2021-03-02 2022-09-09 Boundless Bio, Inc. Ribonucleotide reductase (rnr) inhibitors and uses thereof
WO2023043938A1 (en) * 2021-09-17 2023-03-23 Boundless Bio, Inc. Sulfamide ribonucleotide reductase (rnr) inhibitors and uses thereof
TW202328121A (zh) * 2021-09-17 2023-07-16 美商無界生物公司 環狀磺醯胺核糖核苷酸還原酶(rnr)抑制劑及其用途
JP2025531147A (ja) * 2022-09-13 2025-09-19 バウンドレス バイオ，インク． 環状スルホンアミドリボヌクレオチドレダクターゼ（ｒｎｒ）阻害剤およびその使用
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
ZA991029B (en) * 1998-02-09 1999-09-30 Rhone Poulenc Rorer Pharma Composition and methods for treatment of hiv infections.
AU1182300A (en) * 1998-11-17 2000-06-05 Fuji Photo Film Co., Ltd. Bisaryl compounds and cancer remedies containing the same
AU6894400A (en) * 1999-08-06 2001-03-05 Enzon Pharmaceuticals Inc. Composition and methods for treatment of HIV infection
CA2407799A1 (en) 2000-05-02 2001-11-08 Sugen, Inc. (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
EP1313742A1 (en) 2000-08-31 2003-05-28 Dr. Reddy's Laboratories Ltd. Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
US20060128783A1 (en) 2002-08-09 2006-06-15 Dinsmore Christopher J Tyrosine kinase inhibitors
RU2383536C2 (ru) 2004-08-04 2010-03-10 Тайсо Фармасьютикал Ко., Лтд. Производное триазола
MY142304A (en) 2005-01-31 2010-11-15 Taiho Pharmaceutical Co Ltd Novel pyrimidine nucleoside compound or salt thereof
TW200736234A (en) * 2006-01-17 2007-10-01 Astrazeneca Ab Chemical compounds
ES2458615T3 (es) * 2006-02-03 2014-05-06 Taisho Pharmaceutical Co., Ltd. Derivado de triazol
KR20100031528A (ko) 2007-06-01 2010-03-22 더 트러스티즈 오브 프린스턴 유니버시티 숙주세포 대사경로의 조절을 통한 바이러스 감염 치료
JP2012508215A (ja) 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
AU2015203322B2 (en) 2009-07-20 2016-09-29 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
EP2552453A2 (en) 2010-03-30 2013-02-06 Clavis Pharma ASA Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
AU2015210750B2 (en) 2014-01-31 2020-08-20 Children's Medical Center Corporation Antibody molecules to TIM-3 and uses thereof
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
GB201420239D0 (en) 2014-11-14 2014-12-31 Bergenbio As Biomarker
TWI623316B (zh) 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US10889555B2 (en) * 2016-05-31 2021-01-12 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
AU2017275209C1 (en) 2016-05-31 2020-01-23 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
US20200405697A1 (en) 2017-11-29 2020-12-31 Taiho Pharmaceutical Co., Ltd. Antitumor Agent
AU2018377036B2 (en) 2017-11-29 2022-04-14 Taiho Pharmaceutical Co., Ltd. Sulfonamide compounds and use thereof
KR20220011562A (ko) 2018-04-25 2022-01-28 안나 마트너 급성 골수성 백혈병에서의 재발 위험 감소 및 생존 연장을 위한 방법 및 조성물

Also Published As

Publication number Publication date
SG11202004877UA (en) 2020-06-29
CA3084030C (en) 2023-03-21
ES2969901T3 (es) 2024-05-23
AU2018377036A1 (en) 2020-06-18
TW201925182A (zh) 2019-07-01
CA3084030A1 (en) 2019-06-06
WO2019106579A1 (en) 2019-06-06
MA51224A (fr) 2020-10-07
US20200361883A1 (en) 2020-11-19
EP3717462B1 (en) 2024-01-03
EP3717462A1 (en) 2020-10-07
CN111386260B (zh) 2024-04-30
BR112020010148A2 (pt) 2020-10-13
RU2020121153A3 (es) 2021-12-29
KR20200096261A (ko) 2020-08-11
RU2020121153A (ru) 2021-12-29
KR102480074B1 (ko) 2022-12-21
EP3717462A4 (en) 2021-07-21
PH12020550703A1 (en) 2021-04-26
JP2021504432A (ja) 2021-02-15
MY201832A (en) 2024-03-19
JP6846574B2 (ja) 2021-03-24
TWI762743B (zh) 2022-05-01
US20250223270A1 (en) 2025-07-10
CN111386260A (zh) 2020-07-07
AU2018377036B2 (en) 2022-04-14
US12344588B2 (en) 2025-07-01

Similar Documents

Publication Publication Date Title
PH12020550703A1 (en) Sulfonamide compounds and use thereof
PH12019550235A1 (en) Kinase inhibitors and uses thereof
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
JOP20200110A1 (ar) متبلورات مضادة جديدة لسلسلة من مركبات مضادة للفيروسات
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
TW201613880A (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
PH12017502255B1 (en) Nrf2 regulators
MX2017014035A (es) Formas solidas novedosas.
MX364069B (es) Moduladores de la proteína activadora de 5-lipoxigenasa.
MX2021002382A (es) Sales y formas cristalinas de modulador alosterico positivo gabaa.
TW201613864A (en) Novel compounds
MX2017003254A (es) 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.
PH12017500732B1 (en) Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
TN2017000031A1 (en) Imidazopyridazine compounds
EA201790570A1 (ru) Модуляторы р2х7
GEP201706760B (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
MX2018000515A (es) Compuestos fluorados de cbd, composiciones y usos de los mismos.
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
MX2020006436A (es) Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).